TY - JOUR
T1 - Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma
T2 - clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi
AU - Zaja, Francesco
AU - Salvi, Flavia
AU - Rossi, Maura
AU - Sabattini, Elena
AU - Evangelista, Andrea
AU - Ciccone, Giovannino
AU - Angelucci, Emanuele
AU - Gaidano, Gianluca
AU - Zanni, Manuela
AU - Ladetto, Marco
AU - Chiappella, Annalisa
AU - Vitolo, Umberto
AU - Zinzani, Pier Luigi
AU - Califano, Catello
AU - Tucci, Alessandra
AU - Patti, Caterina
AU - Pileri, Stefano A.
AU - Lenti, Valentina
AU - Piccaluga, Pier Paolo
AU - Cavallo, Federica
AU - Volpetti, Stefano
AU - Perali, Giulia
AU - Assouline, Sarit
AU - Mann, Koren Kathleen
AU - Morin, Ryan
AU - Alcaide, Miguel
AU - Bushell, Kevin
AU - Fanin, Renato
AU - Levis, Alessandro
PY - 2018
Y1 - 2018
N2 - We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.
AB - We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.
KW - Diffuse large B-cell lymphoma
KW - genomic
KW - panobinostat
KW - relapsed/refractory
UR - http://www.scopus.com/inward/record.url?scp=85044938873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044938873&partnerID=8YFLogxK
U2 - 10.1080/10428194.2018.1452208
DO - 10.1080/10428194.2018.1452208
M3 - Article
AN - SCOPUS:85044938873
SN - 1042-8194
VL - 59
SP - 2904
EP - 2910
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -